26 January 2021>: Clinical Research
Predictive Value of a Thyroid-Absorbed Dose with a Shorter Effective Half-Life on Efficacy in Graves Disease Patients Receiving Iodine-131 Therapy
Feng Yu BCEF , Ruiguo Zhang CDF , Guizhi Zhang B , Zhaowei Meng B , Xiaohua Liu B , Yajing He B , Jian Tan D , Renfei Wang ADG*DOI: 10.12659/MSM.928796
Med Sci Monit 2021; 27:e928796
Table 3 Univariate analyses for the categorical variables.
Characteristics | Cured groupn (%) | Uncured groupn (%) | χ2 | p |
---|---|---|---|---|
Gender | 0.465 | 0.495 | ||
Male | 34 (72.3) | 13 (27.7) | ||
Female | 108 (67.1) | 53 (32.9) | ||
Disease course (years) | 0.902 | 0.342 | ||
≤2 | 81 (71.1) | 33 (28.9) | ||
>2 | 61 (64.9) | 33 (35.1) | ||
Disease status | 0.352 | 0.553 | ||
Mild | 52 (85.8) | 27 (34.2) | ||
Moderate-severe | 90 (69.8) | 39 (30.2) | ||
TgAb (IU/ml) | 0.837 | 0.658 | ||
71 (68.3) | 33 (31.7) | |||
40–3000 | 61 (70.1) | 26 (29.9) | ||
>3000 | 10 (58.8) | 7 (41.2) | ||
TpoAb (IU/ml) | 3.034 | 0.223 | ||
35 (62.5) | 21 (37.5) | |||
35–1000 | 56 (75.7) | 18 (24.3) | ||
>1000 | 51 (65.4) | 27 (34.6) | ||
TRAb (IU/L) | 12.064 | |||
5 (55.6) | 4 (44.4) | |||
1.5–15 | 66 (76.7) | 20 (23.3) | ||
15–40 | 50 (72.5) | 19 (27.5) | ||
>40 | 21 (47.7) | 23 (52.3) |